amiridine and Dementia--Vascular

The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer's dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of cognitive disorders did not receive the drug. The positive effect was seen in 53,3% of patients of the main group. The worsening was observed in 40% of patients of the comparison group. The positive effect of the drug on spatial and neurodynamic functions was revealed. No serious side-effects of the treatment were found.

Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aminoquinolines; Cholinesterase Inhibitors; Dementia, Vascular; Female; Humans; Male; Middle Aged; Treatment Outcome

Neuromidin (ipidacrin) was administered to 41 patients, aged 51-79 years, with mild cognitive impairment (MSI) (19) and vascular dementia (22). The drug was prescribed in increasing dosages from 10 to 40 mg during 6 months (a dosage of 40 mg was administered from the 4th week of the treatment). Cognitive functioning was assessed using some clinical scales (CGI, MMSE, GDS etc) and common neuropsychological tests at the base-line and on the 3rd and 6th month of the treatment. A statistically significant therapeutic effect of neuromidin was revealed in both types of cognitive disorders, with the maximal improvement on the first 3 months and further maintenance of the effect. The most distinct dynamics was observed for memory, attention, abstract reasoning, constructive abilities and general mental activity. The drug was well tolerated.

Topics: Aged; Aminoquinolines; Cognition; Cognition Disorders; Dementia, Vascular; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Memory; Middle Aged; Severity of Illness Index; Treatment Outcome